Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the efficacy of scheduled maintenance Transcranial Magnetic Stimulation (TMS) treatment compared to on-demand TMS treatment for symptomatic worsening in patients who have shown a clinical response to acute TMS treatment.
| Condition | Intervention |
|---|---|
|
Major Depressive Disorder |
Device: NeuroStar TMS |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A 12-Month Prospective Randomized Dual-Arm Pilot Study of Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder |
- Examining the proportion of patients maintaining a sustained response throughout a 12 month maintenance treatment phase. [ Time Frame: 12 month evaluation ] [ Designated as safety issue: No ]Sustained response is defined as not requiring TMS reintroduction at every observation point during the maintenance phase.
- Compare the average time to first reintroduction of TMS between the two maintenance treatment arms. [ Time Frame: 12 Month evaluation ] [ Designated as safety issue: No ]Change in depressive symptomatology will be assessed across the duration of maintenance treatment using observer and self-administered efficacy measures.
| Estimated Enrollment: | 50 |
| Study Start Date: | August 2011 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Scheduled Treatment Arm
3 Week TMS taper, clinical assessments and one TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.
|
Device: NeuroStar TMS
120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
|
|
Experimental: Monthly Observational Follow up Arm
3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and TMS reintroduction as needed for clinical deterioration.
|
Device: NeuroStar TMS
120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
|
Detailed Description:
This is a 12-month maintenance treatment study for patients who have responded to a 6 week course of acute TMS treatment for major depressive disorder (MDD). The study will seek to assess the change in depressive symptomatology across the duration of maintenance treatment using observer and self-administered efficacy measures. Describe the efficacy of TMS re-introduction in patients not receiving maintenance pharmacotherapy who show a recurrence of depressive symptoms. Assess the safety and durability of acute TMS therapy followed by maintenance TMS treatment for up to 12 months.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Primary diagnosis by DSM-IV criteria for Major Depressive Episode, single episode or recurrent course of illness, with the additional stipulation of a duration for this episode of ≥ 4 weeks and CGI-S ≥ 4.
- Duration of current episode of depression ≤ 3 years (the definition of an episode is demarcated by a period of ≥ 2 months when the patient did not meet full criteria for the DSM-IV definition of Major Depressive Episode.
- Capable and willing to provide informed consent.
- Signed HIPAA authorization.
- Able to adhere with the treatment schedule, and withdrawal of ongoing pharmacotherapy.
- If currently taking antidepressant pharmacotherapy, must be clinically appropriate to discontinue treatment with those agents.
Exclusion Criteria:
- Investigators, site personnel directly affiliated with this study, and their immediate families (immediate family is defined as a spouse, parent, child or sibling, whether by birth or legal adoption).
Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated):
- Depression secondary to a general medical condition, or substance- induced;
- Seasonal pattern of depression as defined by DSM-IV;
- History of substance abuse or dependence within the past year except nicotine and caffeine);
- Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features in this or previous episodes;
- Bipolar disorder;
- Eating disorder (current or within the past year);
- Obsessive compulsive disorder (lifetime); or
- Post-traumatic stress disorder (current or within the past year).
- An Axis II Personality Disorder, which in the judgment of the Investigator may hinder the patient in completing the procedures required by the study protocol.
Individuals with a clinically defined neurological disorder or insult including, but not limited to:
- Any condition likely to be associated with increased intracranial pressure;
- Space occupying brain lesion;
- History of cerebrovascular accident;
- Transient ischemic attack within two years;
- Cerebral aneurysm;
- Dementia;
- Parkinson's disease;
- Huntington's chorea;
- Multiple sclerosis.
- Increased risk of seizure for any reason, including but not limited to prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or history of significant head trauma with loss of consciousness for ≥ 5 minutes.
- History of treatment with Vagus Nerve Stimulation.
- Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease.
Contacts and Locations| United States, Illinois | |
| Rush University Medical Center | |
| Chicago, Illinois, United States, 60612 | |
| United States, Maryland | |
| Sheppard Pratt Health System | |
| Baltimore, Maryland, United States, 21285 | |
| United States, Nebraska | |
| Premier Psychiatric Group, L.L.C. | |
| Lincoln, Nebraska, United States, 68526 | |
| United States, Rhode Island | |
| Butler Hospital | |
| Providence, Rhode Island, United States, 02906 | |
| United States, South Carolina | |
| Medical University of South Carolina | |
| Charleston, South Carolina, United States, 29425 | |
| United States, Washington | |
| Center for Anxiety and Depression | |
| Mercer Island, Washington, United States, 98040 | |
| Study Director: | David G. Brock, MD | Neuronetics |
More Information
No publications provided
| Responsible Party: | Neuronetics |
| ClinicalTrials.gov Identifier: | NCT01415154 History of Changes |
| Other Study ID Numbers: | 44-03001-000 |
| Study First Received: | August 10, 2011 |
| Last Updated: | February 18, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Neuronetics:
|
TMS Major Depressive Disorder NeuroStar TMS |
Additional relevant MeSH terms:
|
Depressive Disorder Depression Depressive Disorder, Major |
Mood Disorders Mental Disorders Behavioral Symptoms |
ClinicalTrials.gov processed this record on May 16, 2013